Cat. No. 5053
Chemical Name: 4-[4,4-Difluoro-1-(2-fluorophenyl)c
Biological ActivityPotent and selective ERβ agonist (EC50 values are 6 and 5000 nM for ERβ and ERα respectively). Exhibits gender selective neuroprotective effects in a male rat model of Parkinson's disease. Decreases Aβ levels in combination with ACP-105 in a rat model of Alzheimer's disease.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
George et al (2013) Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease. ACS Chem.Neurosci. 4 1537. PMID: 24020966.
McFarland et al (2013) AC-186, a selective nonsteroidal estrogen receptor β agonist, shows gender specific neuroprotection in a Parkinson's disease rat model. ACS Chem.Neurosci. 4 1249. PMID: 23898966.
If you know of a relevant reference for AC 186 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses AC 186 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: AC 186, supplier, AC186, potent, selective, estrogen, receptors, ERbeta, ERb, ERβ, neuroprotection, neuroprotective, parkinsons, alzheimers, parkinson's, alzheimer's, Ab, Abeta, Aβ, amyloidbeta, amyloidb, amyloidβ, Tocris Bioscience, Estrogen and Related Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Synthetic progesterone analogC-DIM 12
Nurr1 activator; inhibits NF-κB-dependent gene expression(S)-Equol
Potent estrogen receptor β (ERβ) agonistAilanthone
Potent inhibitor of androgen receptor (AR)(±)-ML 209
RORγt inverse agonist; suppresses Th17 cell differentiationAGN 193109
High affinity pan-RAR antagonistSR 9243
Selective LXR inverse agonist
September 27 - 30, 2017